Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
Sparsentan Reversibly Decreases Mesangial IgA Deposition in gddY Mice: A Possible Role for Mesangial-Cell -Surface Autoantigen Expression
62nd European Renal Association (ERA) Congress 2025
June 6 - 7, 2025
Austria
Travere and National Kidney Foundation Collaboration
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
Improving Proteinuria With Sparsentan (SPAR) in Patients With IgA Nephropathy (IgAN): A Case Series
Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan
A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan Presented by Travere and ISN
March 11, 2025
Virtual
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis